Abstract:The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RON Delta 160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RON Delta 160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RON Delta 160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3 beta by Ser-9 residue phosphorylation. These effects were channeled by RON Delta 160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RON Delta 160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RON Delta 160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3 beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.

Coordinated Histone Modifications Mediated by A Ctbp Co-Repressor Complex

C-terminal binding protein: Regulator between Viral Infection and Tumorigenesis

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Genome-wide Profiles of CtBP Link Metabolism with Genome Stability and Epithelial Reprogramming in Breast Cancer.

Transcriptional corepressor activity of CtBP1 is regulated by ISG15 modification

A Positive Feedback Loop Between EBP2 and C-Myc Regulates Rdna Transcription, Cell Proliferation, and Tumorigenesis.

Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.

A prominent gene activation role for C-terminal binding protein in mediating PcG/trxG proteins through Hox gene regulation

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

CtBP Modulates Snail-mediated Tumor Invasion in Drosophila.

The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma

A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors.

CREPT Disarms the Inhibitory Activity of HDAC1 on Oncogene Expression to Promote Tumorigenesis

p300/CBP and p300/CBP-associated Factor with Transcriptional Regulation

Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein

Systematical Identification of Cell-Specificity of CTCF-gene Binding Based on Epigenetic Modifications.

CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma.

CtBP1 Interacts with SOX2 to Promote the Growth, Migration and Invasion of Lung Adenocarcinoma.

Feedback regulation between ZBP1 and ß-catenin mRNAs in breast cancer cells

Β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells

C-Terminus of E1A Binding Protein 1 Stimulates Malignant Phenotype in Human Hepatocellular Carcinoma.